Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer

Abstract Whether ICIs combined with chemotherapy can improve outcomes in EGFR-mutant non-small cell lung cancer (NSCLC) remains uncertain. Patients with EGFR-mutant NSCLC and who progressed on first-line EGFR-TKIs treatment were retrospectively collected. We reviewed the outcome of these patients tr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chia-I Shen, Heng-Sheng Chao, Tsu-Hui Shiao, Chi-Lu Chiang, Hsu-Ching Huang, Yung-Hung Luo, Chao-Hua Chiu, Yuh-Min Chen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f9cff9666fad464ca179a238ccc7790b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f9cff9666fad464ca179a238ccc7790b
record_format	dspace
spelling	oai:doaj.org-article:f9cff9666fad464ca179a238ccc7790b2021-12-02T19:06:42ZComparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer10.1038/s41598-021-95628-w2045-2322https://doaj.org/article/f9cff9666fad464ca179a238ccc7790b2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-95628-whttps://doaj.org/toc/2045-2322Abstract Whether ICIs combined with chemotherapy can improve outcomes in EGFR-mutant non-small cell lung cancer (NSCLC) remains uncertain. Patients with EGFR-mutant NSCLC and who progressed on first-line EGFR-TKIs treatment were retrospectively collected. We reviewed the outcome of these patients treated with ICIs or ICIs combined chemotherapy (ICI + C). Total 30 patients were included. The ORR were 9.1% and 25.0% for the ICI and ICI + C groups. The ICI + C group showed the trend of longer progression-free survival and overall survival periods. Patients without the T790M mutation had a significantly longer PFS than did those without this mutation (4.23 [95% CI: 2.75–5.72] vs. 1.70 [95% CI: 0.00–3.51] months, HR:4.45, p = 0.019). ICIs combined with chemotherapy tended to be more effective than ICIs alone in pretreated EGFR-mutant NSCLC. The T790M mutation may be a potential biomarker.Chia-I ShenHeng-Sheng ChaoTsu-Hui ShiaoChi-Lu ChiangHsu-Ching HuangYung-Hung LuoChao-Hua ChiuYuh-Min ChenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chia-I Shen Heng-Sheng Chao Tsu-Hui Shiao Chi-Lu Chiang Hsu-Ching Huang Yung-Hung Luo Chao-Hua Chiu Yuh-Min Chen Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
description	Abstract Whether ICIs combined with chemotherapy can improve outcomes in EGFR-mutant non-small cell lung cancer (NSCLC) remains uncertain. Patients with EGFR-mutant NSCLC and who progressed on first-line EGFR-TKIs treatment were retrospectively collected. We reviewed the outcome of these patients treated with ICIs or ICIs combined chemotherapy (ICI + C). Total 30 patients were included. The ORR were 9.1% and 25.0% for the ICI and ICI + C groups. The ICI + C group showed the trend of longer progression-free survival and overall survival periods. Patients without the T790M mutation had a significantly longer PFS than did those without this mutation (4.23 [95% CI: 2.75–5.72] vs. 1.70 [95% CI: 0.00–3.51] months, HR:4.45, p = 0.019). ICIs combined with chemotherapy tended to be more effective than ICIs alone in pretreated EGFR-mutant NSCLC. The T790M mutation may be a potential biomarker.
format	article
author	Chia-I Shen Heng-Sheng Chao Tsu-Hui Shiao Chi-Lu Chiang Hsu-Ching Huang Yung-Hung Luo Chao-Hua Chiu Yuh-Min Chen
author_facet	Chia-I Shen Heng-Sheng Chao Tsu-Hui Shiao Chi-Lu Chiang Hsu-Ching Huang Yung-Hung Luo Chao-Hua Chiu Yuh-Min Chen
author_sort	Chia-I Shen
title	Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
title_short	Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
title_full	Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
title_fullStr	Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
title_full_unstemmed	Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
title_sort	comparison of the outcome between immunotherapy alone or in combination with chemotherapy in egfr-mutant non-small cell lung cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f9cff9666fad464ca179a238ccc7790b
work_keys_str_mv	AT chiaishen comparisonoftheoutcomebetweenimmunotherapyaloneorincombinationwithchemotherapyinegfrmutantnonsmallcelllungcancer AT hengshengchao comparisonoftheoutcomebetweenimmunotherapyaloneorincombinationwithchemotherapyinegfrmutantnonsmallcelllungcancer AT tsuhuishiao comparisonoftheoutcomebetweenimmunotherapyaloneorincombinationwithchemotherapyinegfrmutantnonsmallcelllungcancer AT chiluchiang comparisonoftheoutcomebetweenimmunotherapyaloneorincombinationwithchemotherapyinegfrmutantnonsmallcelllungcancer AT hsuchinghuang comparisonoftheoutcomebetweenimmunotherapyaloneorincombinationwithchemotherapyinegfrmutantnonsmallcelllungcancer AT yunghungluo comparisonoftheoutcomebetweenimmunotherapyaloneorincombinationwithchemotherapyinegfrmutantnonsmallcelllungcancer AT chaohuachiu comparisonoftheoutcomebetweenimmunotherapyaloneorincombinationwithchemotherapyinegfrmutantnonsmallcelllungcancer AT yuhminchen comparisonoftheoutcomebetweenimmunotherapyaloneorincombinationwithchemotherapyinegfrmutantnonsmallcelllungcancer
_version_	1718377185373323264

Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer

Ejemplares similares